Biote Q2 revenue $49.2M, net loss narrows to $10.5M; procedure revenue grows 7.8% sequentially

biote Corp.

2024-Q2 EPS reported -$0.25 revenue$95,973,000

Revenue of $49.2M; procedure revenue $38.4M, up 7.8% QoQ vs 6.6% in Q1.
Net loss of $(10.5)M (EPS $(0.19)) improved from $(13.1)M ($(0.25)) in Q2 2023.
Adjusted EBITDA of $12.7M; gross profit margin 68.9% with $1.2M inventory step-up from Asteria Health acquisition.
New clinics grew ~30% in H1 2024; 2024 full-year financial guidance reaffirmed.
BioteRx roll-out on track; management plans further geographic and therapeutic wellness expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.